Literature DB >> 7711465

Naloxone does not prevent apomorphine-induced emesis or hypotension in dogs.

J L Montastruc1, M Lapeyre-Mestre, M E Llau, J M Senard, O Rascol, P Montastruc.   

Abstract

Previous data have shown that apomorphine-induced respiratory depression can be reversed by the opiate antagonist, naloxone. The present study investigates the influence of naloxone on cardiovascular changes and vomiting elicited by apomorphine in dogs. In chloralose-anaesthetized animals, naloxone (0.02 mg/kg i.v.) failed to modify either the decrease in blood pressure and the biphasic changes (bradycardia followed by a long-lasting tachycardia in heart rate or the characteristics (occurrence, latency, duration) of the emesis elicited by apomorphine (200 micrograms/kg i.v.). In contrast, in conscious animals, naloxone (0.02 mg/kg i.v.) increased both the number and the duration (but not latency) of vomiting induced by a lower dose of apomorphine (30 micrograms/kg i.v.). These data show that apomorphine-induced vomiting and arterial hypotension do not involve opiate receptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7711465     DOI: 10.1007/bf01821529

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN: 0959-9851            Impact factor:   4.435


  11 in total

1.  Apomorphine: chemistry, pharmacology, biochemistry.

Authors:  F C Colpaert; W F Van Bever; J E Leysen
Journal:  Int Rev Neurobiol       Date:  1976       Impact factor: 3.230

Review 2.  Pharmacological agents affecting emesis. A review (Part I).

Authors:  F Mitchelson
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

Review 3.  On the specificity of naloxone as an opiate antagonist.

Authors:  J Sawynok; C Pinsky; F S LaBella
Journal:  Life Sci       Date:  1979-11-05       Impact factor: 5.037

4.  Cardiovascular effects of apomorphine in humans: evidence for peripheral mechanisms.

Authors:  O J Rascol; J L Montastruc
Journal:  Clin Neuropharmacol       Date:  1986       Impact factor: 1.592

Review 5.  Current status of dopamine agonists in Parkinson's disease management.

Authors:  J L Montastruc; O Rascol; J M Senard
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

6.  Naloxone or haloperidol but not yohimbine reverse apomorphine-induced respiratory depression.

Authors:  J L Montastruc; O Rascol; P Montastruc
Journal:  Clin Neuropharmacol       Date:  1992-10       Impact factor: 1.592

Review 7.  Apomorphine in the evaluation of dopaminergic function in man.

Authors:  S Lal
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1988       Impact factor: 5.067

8.  Pharmacokinetics of apomorphine in parkinsonian patients.

Authors:  E Nicolle; P Pollak; F Serre-Debeauvais; P Richard; C L Gervason; E Broussolle; M Gavend
Journal:  Fundam Clin Pharmacol       Date:  1993       Impact factor: 2.748

9.  Naloxone partly counteracts apomorphine side effects.

Authors:  U Bonuccelli; P Piccini; P Del Dotto; G Rossi; G U Corsini; A Muratorio
Journal:  Clin Neuropharmacol       Date:  1991-10       Impact factor: 1.592

Review 10.  Dopamine agonists in Parkinson's disease: a look at apomorphine.

Authors:  A J Lees
Journal:  Fundam Clin Pharmacol       Date:  1993       Impact factor: 2.748

View more
  1 in total

1.  A study of tolerance to apomorphine.

Authors:  J L Montastruc; M E Llau; J M Senard; M A Tran; O Rascol; P Montastruc
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.